Alimera Sciences, Inc. (ALIM) News

Alimera Sciences, Inc. (ALIM): $5.72

-0.08 (-1.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ALIM News Items

ALIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALIM News Highlights

  • ALIM's 30 day story count now stands at 9.
  • Over the past 27 days, ALIM's stories per day has been in a clear uptrend, growing by about 0.37 per 6 days.
  • EYE and NC are the most mentioned tickers in articles about ALIM.

Latest ALIM News From Around the Web

Below are the latest news stories about Alimera Sciences Inc that investors may wish to consider to help them evaluate ALIM as an investment opportunity.

Alimera Sciences GAAP EPS of -$0.59 misses by $0.17, revenue of $13.95M beats by $0.55M

Alimera Sciences press release (NASDAQ:ALIM): Q4 GAAP EPS of -$0.59 misses by $0.17. Revenue of $13.95M (+1.3% Y/Y) beats by $0.55M....

Seeking Alpha | February 24, 2022

Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -55.26% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Alimera Sciences Reports Fourth Quarter and FY 2021 Results

Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 Full Year 2021 Highlights: Consolidated Net Revenue of $59 Million Up 16% vs 2020 Consolidated Net Product Revenue of $48 MillionU.S. Net Revenue Increased 8% vs. 2020Alimera Granted Exclusive License to Ocumension in April 2021 for a $10 Million Upfront Payment and Up to $89 Million in Additional Sales-Based Milestone Payments ATLANTA, Feb. 24, 2022 (GLOBE NEWSWI

Yahoo | February 24, 2022

Alimera's 3-year data for ILUVIEN shows benefit in diabetic macular edema

Alimera Sciences (NASDAQ:ALIM) reported three-year results of a study called PALADIN evaluating the ILUVIEN implant in patients with diabetic macular edema (DME), an eye complication in people with diabetes. The results, which were published in the journal Ophthalmology, showed that patients with DME who received a single dose of the sustained release implant...

Seeking Alpha | February 23, 2022

Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology

Best corrected visual acuity and central subfield thickness were significantly improved at 36 monthsILUVIEN treatment resulted in a 70.5% reduction in treatment burdenResults confirm that use of prior corticosteroid per the U.S. label mitigates the risk of IOP lowering surgery ATLANTA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal he

Yahoo | February 23, 2022

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern TimeATLANTA, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2021 financial results on Thursday, Febru

Yahoo | February 17, 2022

Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain

ILUVIEN received pricing approval for non-infectious posterior uveitis indication in DecemberATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch ILUVIEN® for non-infectious posterior uveit

Yahoo | February 7, 2022

Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference

ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference, which is being held virtually from February 8 – 11, 2022.

Yahoo | February 4, 2022

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th \- 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time.

Yahoo | January 28, 2022

Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences

ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in two investor conference events in January. Mr. Eiswirth will be presenting at the H.C

Yahoo | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6977 seconds.